Tom Winnifrith Bearcast: Wildcat a lesson from 2001, one of its directors should need no reminding of
I see that Dechra Pharmaceuticals (DPH) has continued to see a share price rise since I last wrote about the stock here in early September. Back then I concluded that it is hard to push back on ‘improving global animal health and welfare’ but it is an expensive multiple to buy this one. So what is the updated view post its first half results?
A couple of years ago I wrote on shares in Dechra Pharmaceuticals (DPH) not particularly complementarily, observing 'I would not want to be paying a 30 times P/E ratio for that...even if its range of equine, cat and other animal pharmaceutical products continues to grow'. It has taken a while, but over recent weeks the stock has broken back above this letter. So on a quiet regulatory news day...what to make of this name following the publication of its full year results today?...
Hello Share Dwellers. At the risk of repeating myself, I’ve long thought our love of pets is a money tree for those in the tame animal industry. One of my favourite pennies Avacta (AVCT) is a case in point, though its share price doggedly fails to take off and it’s also involved in human medicine. So let me suggest another company which does treatments for ailing animals...
I think Dechra Pharmaceuticals (DPH) was the first initial public offering I looked at as a junior analyst on a hedge fund many years ago. It was a bit on the small side for us if I recall, but the essential business of specialist veterinary pharmaceutical products seemed quite sensible to me. After all we love animals almost more than anything else, right?
Search ShareProphets |
Recent Comments |